Holen Sie sich die Stockscreener-App
0.00
100.00%
-10.14
Schlusskurs vom Vortag:
$10.14
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$11.99
Ac Immune Sa Stock (AACIU) Company Profile
Firmenname
Ac Immune Sa
Sektor
Branche
Telefon
215.543.6886
Adresse
89 NEXUS WAY, CARMANA BAY
Compare AACIU vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AACIU
Ac Immune Sa
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
512.13 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.65 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
166.82 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
992.58 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.04 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ac Immune Sa Aktie (AACIU) Neueste Nachrichten
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - Stock Titan
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune2026 Funding Rounds & List of Investors - Tracxn
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway - TipRanks
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune stock gains on early Phase 1 trial results - Investing.com
AC Immune posts trial data for inflammatory drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports phase 1 safety data for NLRP3 inhibitor By Investing.com - Investing.com Nigeria
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764 - TipRanks
AC Immune reports phase 1 safety data for NLRP3 inhibitor - Investing.com India
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - The Manila Times
AC Immune (NASDAQ: ACIU) advances NLRP3 pill into heart-risk trial - Stock Titan
AC (ACIU) Levels: Advances 0.39% to $2.58 in the Latest Reading; Chart View: $2.45 and $2.71 Define the Nearby Reference LevelsInside Day Breakout - vinanet.vn
AC Immune takes Parkinson's vaccine into US trials as Phase II data near - AllSci
ACIU Q2 2026 Earnings: Surprise EPS Beat of 117.61% Offers Little Support as Shares Slip 1.91%Quarterly Financial Update - vinanet.vn
ACIU Looks 33.6% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
AC Immune receives FDA fast track status for parkinson’s drug By Investing.com - Investing.com Nigeria
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease - TipRanks
AC Immune receives FDA fast track status for parkinson’s drug - Investing.com
AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104 - Stock Titan
AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate - Stock Titan
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) - Yahoo Finance UK
AC Immune SA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Analyst Reiterates Buy on AC Immune as 2H26 Catalysts Approach; Price Target Maintained at $12 - tipranks.com
AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit - Sahm
ACIU Reiterated by BTIG -- Maintains Price Target at $8.00 - GuruFocus
AC Immune SA reports results for the quarter ended June 30Earnings Summary - TradingView
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K - TipRanks
AC Immune: Q2 Earnings Snapshot - Barchart.com
AC Immune First Half 2026 Financial and Corporate Update - The Manila Times
Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss - Stock Titan
AC Immune’s Parkinson’s Trial Gets a $4 Million Grant - Stock Titan
AC Immune (ACIU) Posts Modest 2.2% Gain as Shares Trade Above $2.30 SupportMFI Overbought - dars.gov.et
ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesAnalyst Drop Coverage - vinanet.vn
ACIU Q1 2026 Earnings: Modest EPS Beat Drives 4.41% Share Gain for Clinical-Stage Alzheimer's DeveloperPost-Earnings Drift - vinanet.vn
ACIU Q1 2026 Earnings: Narrowed Loss Beats Expectations as Pipeline AdvancesPretax Income Report - vinanet.vn
AC Immune SA (ACIU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AC Immune SA (ACIU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AC Immune SA (ACIU) Institutional Confidence - TradingKey
Finanzdaten der Ac Immune Sa-Aktie (AACIU)
Es liegen keine Finanzdaten für Ac Immune Sa (AACIU) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.16%
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):